US Medical Communications

1. Please select one of the following. If you are a health care professional, please make selections from the appropriate lists:
I am a health care professional.
Profession
Specify if other
Specialty

I am a patient or consumer.

2. Please indicate the product(s) for which you would like information:

FLUVIRIN^®
RABAVERT^®
MSDS Request
Other

3. Please give us a little information about yourself:
For Information on our Terms of Use and our Privacy Statement, please click on the links below.

Social Title	Professional Title
First Name	Initial Last Name
Institution
Department
Address

City	State/Province/Territory Zip
Country
Telephone	Fax
Email Address

4. State your request here. Please be specific.

US Medical Communications

US Medical Communications is the point of contact for inquiries about our marketed vaccine products, pipeline products, and general vaccine-related questions. Business hours are 8:00am - 5:00pm Eastern Time. Call or submit your question online.

1-800-244-7668, Option 2

Online request form

News

06 May 2008
First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra*. Novartis expects Menveo to be first quadrivalent meningococcal vaccine to protect from early infancy through adulthood. More than 8 million infants and adolescents in the US and a significant number of children and travellers globally could benefit from Menveo[1]

09 January 2008
Data in JAMA show Menveo may provide infants protection against four of the most common meningococcal serogroups - A, C, W-135 and Y. Menveo stimulates broad immune response against meningococcal disease in infants from two months old